Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:alsoKnownAs |
gptkb:temsirolimus
|
| gptkbp:approvalYear |
2007
|
| gptkbp:approvedBy |
renal cell carcinoma
|
| gptkbp:ATCCode |
gptkb:L01XE09
|
| gptkbp:CASNumber |
gptkb:162635-04-3
|
| gptkbp:chemicalClass |
rapamycin analog
|
| gptkbp:developedBy |
gptkb:Wyeth_Pharmaceuticals
|
| gptkbp:hasMolecularFormula |
C56H87NO16
|
| https://www.w3.org/2000/01/rdf-schema#label |
CCI-779
|
| gptkbp:mechanismOfAction |
mTOR inhibitor
|
| gptkbp:relatedTo |
gptkb:everolimus
gptkb:sirolimus |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:anemia
fatigue rash hyperglycemia |
| gptkbp:target |
gptkb:mTOR_protein
|
| gptkbp:usedFor |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:temsirolimus
|
| gptkbp:bfsLayer |
6
|